Description: Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.
Home Page: www.windtreetx.com
2600 Kelly Road
Warrington,
PA
18976-3622
United States
Phone:
215 488 9300
Officers
| Name | Title |
|---|---|
| Mr. Craig E. Fraser | Pres, CEO & Director |
| Dr. Steven G. Simonson | Sr. VP & Chief Medical Officer |
| Mr. John P. Hamill | Sr. VP & CFO |
| Mr. Eric L. Curtis M.B.A. | Sr. VP & COO |
| Mr. George Cox | VP of Manufacturing & Supply Chain and Technical Operations |
| Dr. Pratap Paruchuru | Exec. Director of Clinical Devel. |
| Ms. Tracy Rarick | Head of Operations & Program Management |
| Dr. Ronald L. Dundore | Exec. Director of Regulatory Affairs & Quality |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |